Intermediate coronary syndrome

Summary

Intermediate coronary syndrome (MONDO:0006805) is a disease with 12 GWAS associations across 7 studies and 149 clinical trials. Top therapeutic interventions include enoxaparin sodium, ticagrelor, and cangrelor. A subtype of coronary artery disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• GWAS associations: 12
• Clinical trials: 149

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	intermediate coronary syndrome
Mondo ID	MONDO:0006805
EFO	EFO:1000985
MeSH	D000789
DOID	DOID:8805
ICD-10-CM	I20.0
ICD-11	253490233
UMLS	C0002965
MedGen	296
MedDRA	10022554
Is cancer (heuristic)	no

Also known as: angina at rest · anginal chest pain at rest · impending infarction · Preinfarction angina · unstable angina · worsening angina

Data availability: 12 GWAS associations (7 studies).

Disease family

This is a subtype of coronary artery disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › arterial disorder › coronary artery disorder › intermediate coronary syndrome

Related subtypes (11): coronary vasospasm, postoperative ventricular dysfunction, coronary aneurysm, coronary stenosis, coronary thrombosis, coronary artery disease, autosomal dominant, 1, coronary artery disease, autosomal dominant 2, coronary artery congenital malformation, coronary atherosclerosis, nonobstructive coronary artery disease, fibromuscular dysplasia of the coronary arteries

Genetics & variants

GWAS landscape

12 GWAS associations across 7 studies. Top hits map to 5 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs4977575	4e-57	CDKN2B-AS1	C	0.18
rs1333047	5e-46	CDKN2B-AS1	A	0.17
rs10455872	7e-45	LPA	A	0.28
chr1:109817838	4e-18		T	0.12
rs12740374	3e-17	CELSR2	G	0.11
rs10757274	6e-16	CDKN2B-AS1	?
rs9349379	2e-12	PHACTR1	A	0.08
chr8:19870044	3e-12		G	0.09
rs1537372	8e-12	CDKN2B-AS1	?	1.24
rs322	3e-11	LPL	A	0.08

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90475930	Verma A	2024	16,513	418,345	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90651205	Liu TY	2025	7,442	212,336	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90436072	Zhou W	2018	5,181	377,103	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90477864	Verma A	2024	3,328	114,240	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480129	Verma A	2024	3,328	114,240	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90477863	Verma A	2024	1,613	56,592	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90837504	Koyama S	2025	0	0	Genetics and context for precision health in Greater Boston.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	1
Tier 3: regulatory	1
Tier 4: intronic/intergenic	8

MAF distribution

Bucket	Variants
common (>=0.05)	10
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	5
unknown	2
regulatory_region_variant	1
intergenic_variant	1
3_prime_UTR_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs4977575	9	22124745	C>G,T	0.496	regulatory_region_variant	CDKN2B-AS1	4e-57	Tier 3: regulatory
rs1333047	9	22124505	A>C,G,T	0.424	intergenic_variant	CDKN2B-AS1	5e-46	Tier 4: intronic/intergenic
rs10455872	6	160589086	A>G	0.069	intron_variant	LPA	7e-45	Tier 4: intronic/intergenic
chr1:109817838				0.212			4e-18	Tier 4: intronic/intergenic
rs12740374	1	109274968	G>T	0.225	3_prime_UTR_variant	CELSR2	3e-17	Tier 2: splice/UTR
rs10757274	9	22096056	A>C,G,T	0.05	intron_variant	CDKN2B-AS1	6e-16	Tier 4: intronic/intergenic
rs9349379	6	12903725	A>C,G,T	0.335	intron_variant	PHACTR1	2e-12	Tier 4: intronic/intergenic
chr8:19870044				0.264			3e-12	Tier 4: intronic/intergenic
rs1537372	9	22103184	G>A,T	0.05	intron_variant	CDKN2B-AS1	8e-12	Tier 4: intronic/intergenic
rs322	8	19961706	A>C	0.296	intron_variant	LPL	3e-11	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

3 approved drugs — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Status
Abciximab	Approved (phase 4)
Bivalirudin	Approved (phase 4)
Eptifibatide	Approved (phase 4)

9 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Dextrose	Phase 3
Enoxaparin Sodium	Phase 3
Estrogens, Conjugated	Phase 3
Insulin Human	Phase 3
Potassium Chloride	Phase 3
Progesterone	Phase 3
Rivaroxaban	Phase 3
Argatroban	Phase 2
Heparin	Phase 2

Clinical trials & evidence

Clinical trials

Clinical trials: 149.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	90
PHASE4	29
PHASE3	18
PHASE2	10
PHASE2/PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00139802	PHASE4	COMPLETED	DANish Multicenter STENT Trial
NCT00181818	PHASE4	COMPLETED	Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease
NCT00276432	PHASE4	COMPLETED	Diagnosis and Treatment of Acute Coronary Syndrome in the ED & the Impact of Rapid Bedside cTnl on Outcome.
NCT00337116	PHASE4	WITHDRAWN	Intravenous Isosorbide Dinitrate Versus Sublingual Isosorbide Dinitrate for the Relief of Acute Anginal Episodes in Acute Coronary Syndrome (ACS) Patients
NCT00518245	PHASE4	TERMINATED	Ischemia Driven Enoxaparin Therapy in ACS Presenting as Low Risk (IDEAL)
NCT01204320	PHASE4	TERMINATED	A COMparison Between PAClitaxel-coated Balloon and pacliTaxel-eluting Stent in the Treatment of In-Stent Restenosis (COMPACT-ISR)
NCT01372839	PHASE4	UNKNOWN	Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome
NCT01637012	PHASE4	COMPLETED	Prospective, Single-arm, Multicenter Study for Evaluation the Safety and Effectiveness of the ALEX Stent in a Real-world Setting of Percutaneous Coronary Interventions in Patients With Coronary Heart Disease
NCT01826552	PHASE4	COMPLETED	Comparison of the Angiographic Result of the Orsiro Hybrid Stent With Resolute Integrity Stent
NCT01895751	PHASE4	COMPLETED	Conservative Non-Invasive Versus Routine Invasive Management in Coronary Artery Bypass Surgery Patients with Non ST Elevation Elevation Acute Coronary Syndrome
NCT02032290	PHASE4	UNKNOWN	Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel
NCT02032303	PHASE4	UNKNOWN	Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor .
NCT02037412	PHASE4	TERMINATED	Impact of Ticagrelor on the Endothelial Healing Following Drug-eluting Stent Implantation in the Patients With Acute Coronary Syndrome
NCT02317198	PHASE4	COMPLETED	Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly
NCT02601157	PHASE4	COMPLETED	Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial
NCT02618837	PHASE4	UNKNOWN	Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers
NCT02723981	PHASE4	WITHDRAWN	COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials
NCT02733341	PHASE4	COMPLETED	The Effect of IV Cangrelor and Oral Ticagrelor Study
NCT03037047	PHASE4	UNKNOWN	Efficacy and Safety of Salvianolate Injection in Elderly Patients With Unstable Angina Pectoris
NCT03171597	PHASE4	UNKNOWN	Research on the Clinical Effect of Effective Prescription in Treating Unstable Angina.
NCT03179514	PHASE4	UNKNOWN	Effect of Gualou Xiebai Banxia Decoction With Danshen Decoction in Treating Unstable Angina.
NCT03179527	PHASE4	UNKNOWN	Research on the Clinical Effect of Shuanghe Decoction in Treating Unstable Angina.
NCT03179618	PHASE4	UNKNOWN	Research on the Clinical Effect of Xuefu Zhuyu Decoction in Treating Unstable Angina.
NCT03363035	PHASE4	COMPLETED	Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome
NCT03980990	PHASE4	UNKNOWN	Metformin Continuation Versus Interruption Following Coronary Angiography: a Pilot Randomized Controlled Trial
NCT04090281	PHASE4	UNKNOWN	Implementing Precision Medicine Approaches to Guide Anti-platelet Selection
NCT04442919	PHASE4	COMPLETED	Influence of METHoxyflurane on ANtiplatelet Effect of Ticagrelor in Patients With Unstable Angina Pectoris
NCT04661709	PHASE4	UNKNOWN	Efficacy and Safety of Wen Xin Granules for the Treatment of Unstable Angina Pectoris
NCT05740371	PHASE4	COMPLETED	Safety of Argatroban Infusion in Conduction Disturbances
NCT00043784	PHASE3	COMPLETED	SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes
NCT00066898	PHASE3	UNKNOWN	ARISE - Aggressive Reduction of Inflammation Stops Events
NCT00093158	PHASE3	COMPLETED	Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)
NCT00250471	PHASE3	COMPLETED	PROTECT-TIMI 30 Trial
NCT00336830	PHASE3	COMPLETED	Improving Cardiac Rehabilitation Participation in Women and Men
NCT00372671	PHASE3	COMPLETED	Evaluation of an Introductory Videotape Intervention to Improve Cardiac Rehabilitation Participation
NCT00473863	PHASE3	UNKNOWN	Coronary Computed Tomographic Angiography in Emergency Department Chest Pain Patients at Intermediate Risk of Acute Coronary Syndrome
NCT00774475	PHASE3	UNKNOWN	Dual Antiplatelet Therapy Tailored on the Extent of Platelet Inhibition
NCT00809965	PHASE3	COMPLETED	An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
NCT00857441	PHASE2/PHASE3	COMPLETED	Drug-eluting Balloon in Bifurcations Trial
NCT01016041	PHASE3	COMPLETED	A Trial of Everolimus-eluting Stents and Paclitaxel-eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ENOXAPARIN SODIUM	4	5
TICAGRELOR	4	4
CANGRELOR	4	3
RIVAROXABAN	4	3
PRASUGREL	4	2
TIROFIBAN	4	2
TRIMETAZIDINE	4	2
ARGATROBAN	4	1
ATORVASTATIN	4	1
CAPLACIZUMAB	4	1
DABIGATRAN ETEXILATE	4	1
EPTIFIBATIDE	4	1
HYDROXYETHYL STARCH 130/0.4	4	1
NITROGLYCERIN	4	1
SODIUM BICARBONATE	4	1
STREPTOKINASE	4	1
VITAMIN E	4	1
DABIGATRAN	3	1
MAXACALCITOL	3	1
SERINE	3	1
SUCCINOBUCOL	3	1
CMX-2043	2	1
CHEMBL4303245	0	4
ENOXAPARIN	0	3
CHEMBL255682	0	1
CHEMBL502016	0	1
CHEMBL59461	0	1
ALPHA-TOCOPHEROL	0	1